Form 4: Third Harmonic Bio Executive Acquires 210,000 Stock Options
SEC Form 4 Filing
Dennis Dean, Chief Nonclinical Development Officer of Third Harmonic Bio, Inc., acquired 210,000 employee stock options on May 16, 2024.
Summary
- On May 16, 2024, Dennis Dean, the Chief Nonclinical Development Officer of Third Harmonic Bio, Inc., acquired 210,000 employee stock options.
- The exercise price of these options is $14.23.
- 25% of the shares will vest on May 16, 2025, and the remaining shares will vest monthly until fully vested, contingent upon continued service.
- The options expire on May 15, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it can signal confidence from the executive in the company's future.
Positives
- The acquisition of stock options by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is important for maintaining investor confidence.
Stakeholder Impact
- The acquisition of stock options by a key executive can positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Date of transaction: Dennis Dean acquired 210,000 employee stock options. |
| 05/16/2025 | First vesting date: 25% of the options begin to vest. |
| 05/15/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.